专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019134048A1 MODIFIED ORTHOPOXVIRUS VECTORS 审中-公开
公开(公告)号：WO2019134048A1
公开(公告)日：2019-07-11
申请号：PCT/CA2019/050014
申请日：2019-01-04
申请人： BELL, John C. , LE BOEUF, Fabrice , HUH, Michael S. , TANG, Matthew Y. , PELIN, Adrian
发明人： BELL, John C. , LE BOEUF, Fabrice , HUH, Michael S. , TANG, Matthew Y. , PELIN, Adrian
IPC分类号： C12N15/863 , C12N15/12 , C12N15/13 , C12N15/37 , C12N15/39 , C12N15/52 , C12N7/01
摘要： The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.

2. 发明申请

WO2008011726A1 STAGED IMMUNE-RESPONSE MODULATION IN ONCOLYTIC THERAPY FIELD 审中-公开
标题翻译：标签治疗中的免疫应答调控
公开(公告)号：WO2008011726A1
公开(公告)日：2008-01-31
申请号：PCT/CA2007/001340
申请日：2007-07-27
申请人： JENNEREX BIOTHERAPEUTICS ULC , BELL, John C. , BREITBACH, Caroline Judith , ATKINS, Harry
发明人： BELL, John C. , BREITBACH, Caroline Judith , ATKINS, Harry
IPC分类号： A61K35/76 , A61K45/06 , A61P35/00 , A61P37/02
CPC分类号： A61K45/06 , A61K31/00 , A61K35/766 , A61K38/191 , A61K38/193 , A61K38/195 , A61K38/2053 , A61K38/484 , C12N2760/20232 , A61K2300/00
摘要： The invention provides methods for treating tumours, such as solid tumours, in a host. The methods may involve infecting the tumour with an amount of one or more strains of oncolytic virus. The virus will generally be selected to be effective to cause a lytic infection of tumour cells within the tumour. In various embodiments, the host neutrophil response to the lytic infection may be modulated, so that during the course of the lytic infection, the host has an initial neutrophil response and a secondary neutrophil response, these two responses being different in some material respect. For example, the secondary neutrophil response may mediate a greater degree of apoptotic killing of tumour cells than does the initial neutrophil response.
摘要翻译：本发明提供了在宿主中治疗肿瘤例如实体瘤的方法。所述方法可包括用一定量的一种或多种溶瘤病毒菌株感染肿瘤。病毒通常被选择为有效引起肿瘤内肿瘤细胞的裂解感染。在各种实施方案中，可以调节宿主嗜中性粒细胞对溶解感染的反应，使得在溶解感染过程中，宿主具有初始嗜中性粒细胞反应和继发嗜中性粒细胞反应，这两种反应在某些材料方面是不同的。例如，次中性嗜中性粒细胞反应可能介导比初始嗜中性粒细胞反应更大程度的细胞凋亡的肿瘤细胞。

3. 发明申请

WO2004085659A2 MUTANT VIRUSES AND USES THEREOF 审中-公开
标题翻译：突变病毒及其用途
公开(公告)号：WO2004085659A2
公开(公告)日：2004-10-07
申请号：PCT/CA2004/000463
申请日：2004-03-29
申请人： OTTAWA HEALTH RESEARCH INSTITUTE , WELLSTAT BIOLOGICS CORPORATION , BELL, John, C. , LICHTY, Brian, D. , STOJDL, David, F.
发明人： BELL, John, C. , LICHTY, Brian, D. , STOJDL, David, F.
IPC分类号： C12N15/86
CPC分类号： C07K14/005 , A61K35/766 , A61K39/12 , A61K39/205 , A61K39/39 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , C07K2319/60 , C12N7/00 , C12N15/86 , C12N2760/20222 , C12N2760/20232 , C12N2760/20234 , C12N2760/20243 , C12N2760/20261 , C12N2830/00 , C12N2830/85
摘要： The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo . The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.
摘要翻译：本发明提供了在体内减毒的受感染细胞中阻断mRNA或蛋白质的核转运能力降低的突变病毒。本发明的突变病毒还可能能够触发正常宿主细胞的抗病毒系统，同时对这些系统的作用保持敏感。本发明还提供了在一系列应用中使用突变病毒，包括但不限于作为治疗癌症和感染的治疗剂，作为疫苗和佐剂，作为病毒载体，以及作为溶瘤和细胞溶解剂选择性裂解恶性或感染细胞。

4. 发明申请

WO2011070440A3 ONCOLYTIC RHABDOVIRUS 审中-公开
标题翻译：麻痹RHABDOVIRUS
公开(公告)号：WO2011070440A3
公开(公告)日：2011-09-01
申请号：PCT/IB2010003396
申请日：2010-12-10
申请人： OTTAWA HOSPITAL RES INST , BELL JOHN C , STOJDL DAVID F
发明人： BELL JOHN C , STOJDL DAVID F
IPC分类号： C12N7/01 , A61K35/76 , A61P35/00 , C07K14/145 , C12N7/04 , C12N15/86
CPC分类号： C12N7/00 , A61K35/766 , A61K35/768 , A61K45/06 , C12N2760/20021 , C12N2760/20032 , C12N2760/20062 , C12N2760/20071 , A61K2300/00
摘要： Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
摘要翻译：本发明的实施方案包括与马拉巴病毒有关的组合物和方法及其作为抗癌治疗剂的用途。这种弹状病毒在体外和体内具有肿瘤细胞杀伤性质。

5. 发明申请

WO2004085659A3 MUTANT VESICULAR STOMATITIS VIRUSES AND USES THEREOF 审中-公开
标题翻译：突变体病毒性病毒及其用途
公开(公告)号：WO2004085659A3
公开(公告)日：2004-12-09
申请号：PCT/CA2004000463
申请日：2004-03-29
申请人： OTTAWA HEALTH RESEARCH INST , WELLSTAT BIOLOGICS CORP , BELL JOHN C , LICHTY BRIAN D , STOJDL DAVID F
发明人： BELL JOHN C , LICHTY BRIAN D , STOJDL DAVID F
IPC分类号： A61K35/76 , A61K38/16 , A61K39/205 , A61K39/39 , A61K48/00 , C07K14/145 , C12N7/04 , C12N15/86
CPC分类号： C07K14/005 , A61K35/766 , A61K39/12 , A61K39/205 , A61K39/39 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , C07K2319/60 , C12N7/00 , C12N15/86 , C12N2760/20222 , C12N2760/20232 , C12N2760/20234 , C12N2760/20243 , C12N2760/20261 , C12N2830/00 , C12N2830/85
摘要： The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.
摘要翻译：本发明提供了在体内减毒的感染细胞中阻断mRNA或蛋白质的核转运能力降低的突变病毒。本发明的突变病毒还可能能够触发正常宿主细胞的抗病毒系统，同时对这些系统的作用保持敏感。本发明还提供了在一系列应用中使用突变病毒，包括但不限于作为治疗癌症和感染的治疗剂，作为疫苗和佐剂，作为病毒载体，以及作为溶瘤和细胞溶解剂选择性裂解恶性或感染细胞。

6. 发明申请

WO2004078206A1 USE OF MYXOMA VIRUS FOR THE THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRAL INFECTION 审中-公开
标题翻译：用于治疗癌症和慢性病毒感染的MYXOMA病毒的使用
公开(公告)号：WO2004078206A1
公开(公告)日：2004-09-16
申请号：PCT/CA2004/000341
申请日：2004-03-08
申请人： ROBARTS RESEARCH INSTITUTE , MCFADDEN, Grant , BELL, John, C.
发明人： MCFADDEN, Grant , BELL, John, C.
IPC分类号： A61K39/275
CPC分类号： A61K35/768 , C12N2710/24032
摘要： The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.
摘要翻译：本发明涉及粘液瘤病毒的治疗用途。粘液瘤病毒可以选择性感染具有缺陷先天性抗病毒应答的细胞，包括对干扰素无反应的细胞，可用于治疗特征在于存在这种细胞（包括癌症）的疾病。

7. 发明申请

WO2019134049A1 MODIFIED VACCINIA VECTORS 审中-公开
公开(公告)号：WO2019134049A1
公开(公告)日：2019-07-11
申请号：PCT/CA2019/050015
申请日：2019-01-04
申请人： BELL, John C. , LE BOEUF, Fabrice , HUH, Michael S. , TANG, Matthew Y. , KELLER, Brian Andrew , PELIN, Adrian
发明人： BELL, John C. , LE BOEUF, Fabrice , HUH, Michael S. , TANG, Matthew Y. , KELLER, Brian Andrew , PELIN, Adrian
IPC分类号： C12N15/863 , A61K35/76 , A61K35/768 , A61P35/00 , C07K14/07 , C12N15/39 , C12N5/10 , C12N7/01
摘要： The disclosure relates to modified vaccinia virus vectors derived from the Copenhagen strain of vaccinia virus, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified Copenhagen-derived vaccinia virus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.

8. 发明申请

WO2010020056A1 ENGINEERED SYNERGISTIC ONCOLYTIC VIRAL SYMBIOSIS 审中-公开
标题翻译：工程协同毒理学病毒学意义
公开(公告)号：WO2010020056A1
公开(公告)日：2010-02-25
申请号：PCT/CA2009/001176
申请日：2009-08-20
申请人： OTTAWA HOSPITAL RESEARCH INSTITUTE , BELL, John C. , LE BOEUF, Fabrice
发明人： BELL, John C. , LE BOEUF, Fabrice
IPC分类号： A61K35/76 , A61P35/00
CPC分类号： A61K38/162 , A61K35/76 , A61K35/766 , A61K38/193 , C12N2710/24132 , C12N2760/20232 , A61K2300/00
摘要： In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host.
摘要翻译：一方面，本发明提供了通过用两种或多种病毒株感染宿主组织来优先杀死宿主例如癌细胞中的靶增殖细胞的方法。可以选择病毒株以提供协同和共生作用，其涉及目标增殖细胞中的同时溶解感染。在选择的实施方案中，选择病毒使得第一毒力因子在被第一病毒感染的增殖细胞中的表达增加了第二病毒的溶解作用; 并且第二种毒力因子在用第二种病毒感染的增殖细胞中的表达增加了第一种病毒的溶解作用。可以选择第一和第二病毒的基因组，使得它们与宿主细胞中的病毒基因组之间的重组不相容。

9. 发明申请

WO2008011726A8 STAGED IMMUNE-RESPONSE MODULATION IN ONCOLYTIC THERAPY 审中-公开
标题翻译：标签治疗中的免疫应答调控
公开(公告)号：WO2008011726A8
公开(公告)日：2008-05-22
申请号：PCT/CA2007001340
申请日：2007-07-27
申请人： OTTAWA HEALTH RESEARCH INST , BELL JOHN C , BREITBACH CAROLINE JUDITH , ATKINS HARRY
发明人： BELL JOHN C , BREITBACH CAROLINE JUDITH , ATKINS HARRY
IPC分类号： A61K35/76 , A61K45/06 , A61P35/00 , A61P37/02
CPC分类号： A61K45/06 , A61K31/00 , A61K35/766 , A61K38/191 , A61K38/193 , A61K38/195 , A61K38/2053 , A61K38/484 , C12N2760/20232 , A61K2300/00
摘要： The invention provides methods for treating tumours, such as solid tumours, in a host. The methods may involve infecting the tumour with an amount of one or more strains of oncolytic virus. The virus will generally be selected to be effective to cause a lytic infection of tumour cells within the tumour. In various embodiments, the host neutrophil response to the lytic infection may be modulated, so that during the course of the lytic infection, the host has an initial neutrophil response and a secondary neutrophil response, these two responses being different in some material respect. For example, the secondary neutrophil response may mediate a greater degree of apoptotic killing of tumour cells than does the initial neutrophil response.
摘要翻译：本发明提供了在宿主中治疗肿瘤例如实体瘤的方法。所述方法可包括用一定量的一种或多种溶瘤病毒菌株感染肿瘤。病毒通常被选择为有效引起肿瘤内肿瘤细胞的裂解感染。在各种实施方案中，可以调节宿主嗜中性粒细胞对溶解感染的反应，使得在溶解感染过程中，宿主具有初始嗜中性粒细胞反应和继发嗜中性粒细胞反应，这两种反应在某些材料方面是不同的。例如，次中性嗜中性粒细胞反应可能介导比初始嗜中性粒细胞反应更大程度的细胞凋亡的肿瘤细胞。

10. 发明申请

WO2004085658A1 MUTANT VESICULAR STOMATITIS VIRUSES AND USE THEREOF 审中-公开
标题翻译：突变型VESICULAR STOMATITIS病毒及其使用
公开(公告)号：WO2004085658A1
公开(公告)日：2004-10-07
申请号：PCT/CA2004/000460
申请日：2004-03-29
申请人： OTTAWA HEALTH RESEARCH INSTITUTE , WELLSTAT BIOLOGICS CORPORATION , BELL, John, C. , LICHTY, Brian, D. , STOJDL, David, F.
发明人： BELL, John, C. , LICHTY, Brian, D. , STOJDL, David, F.
IPC分类号： C12N15/86
CPC分类号： C07K14/005 , A61K35/766 , A61K39/12 , A61K39/205 , A61K39/39 , A61K48/00 , A61K2039/5254 , A61K2039/5256 , C07K2319/60 , C12N7/00 , C12N15/86 , C12N2760/20222 , C12N2760/20232 , C12N2760/20234 , C12N2760/20243 , C12N2760/20261 , C12N2830/00 , C12N2830/85
摘要： The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo . The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.
摘要翻译：本发明提供了在体内减毒的受感染细胞中阻断mRNA或蛋白质的核转运能力降低的突变病毒。本发明的突变病毒还可能能够触发正常宿主细胞的抗病毒系统，同时对这些系统的作用保持敏感。本发明还提供了在一系列应用中使用突变病毒，包括但不限于作为治疗癌症和感染的治疗剂，作为疫苗和佐剂，作为病毒载体，以及作为溶瘤和细胞溶解剂选择性裂解恶性或感染细胞。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式